ES8400770A1 - Un metodo para producir una molecula de adn recombinante caracterizada por una secuencia de adn codificada de un coni- peptido semejante al, interferon humano. - Google Patents

Un metodo para producir una molecula de adn recombinante caracterizada por una secuencia de adn codificada de un coni- peptido semejante al, interferon humano.

Info

Publication number
ES8400770A1
ES8400770A1 ES509222A ES509222A ES8400770A1 ES 8400770 A1 ES8400770 A1 ES 8400770A1 ES 509222 A ES509222 A ES 509222A ES 509222 A ES509222 A ES 509222A ES 8400770 A1 ES8400770 A1 ES 8400770A1
Authority
ES
Spain
Prior art keywords
polypeptides
human interferon
dna sequences
recombinant dna
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES509222A
Other languages
English (en)
Other versions
ES509222A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27224760&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8400770(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen NV filed Critical Biogen NV
Publication of ES8400770A1 publication Critical patent/ES8400770A1/es
Publication of ES509222A0 publication Critical patent/ES509222A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/811—Interferon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/832—Bacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/832—Bacillus
    • Y10S435/839—Bacillus subtilis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/848—Escherichia
    • Y10S435/849—Escherichia coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UN METODO DE PRODUCIR UNA MOLECULA DE ADN RECOMBINANTE CARACTERIZADA POR UNA SECUENCIA DE ADN CODIFICADORA DE UN POLIPEPTIDO SEMEJANTE AL INTERFERON HUMANO.SE EFECTUAN LAS SIGUIENTES ETAPAS: 1.O)ESCINDIR CON UNA ENDONUCLEASA DE RESTRICCION, UN VEHICULO DE CLONACION QUE CONTIENE UN MARCADOR ADECUADO PARA USO EN LA IDENTIFICACION DE CELULAS TRANSFORMADAS. 2.O)INSERTAR UNA SECUENCIA DE ADN LA CUAL SE SELECCIONA DE ENTRE Z-PBR322(PST)/ HCIF-4C, Z-PBR322(PST)/ HCIF-2H, Z-PBR322(PST)/ HCIF-SN35, Z-PBR322(PST)/ HCIF-SN42, Z-PKT287(PST)/ HCIF-2H-AH6, SECUENCIAS DE ADN QUE SE HIBRIDAN PARADAR CUALQUIERA DE LAS INSERCIONES DE ADN PRECEDENTES Y QUE CODIFICAN UN POLIPEPTIDO DEL TIPO IFN-A Y SECUENCIAS DE ADN QUE CODIFICAN POR EXPRESION UN POLIPEPTIDO CODIFICADO POR EXPRESION DE LAS SECUENCIAS DE ADN PRECEDENTES.
ES509222A 1980-01-08 1982-02-01 Un metodo para producir una molecula de adn recombinante caracterizada por una secuencia de adn codificada de un coni- peptido semejante al, interferon humano. Granted ES509222A0 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP80300079 1980-01-08
EP80301100 1980-04-03
GB8031737 1980-10-02

Publications (2)

Publication Number Publication Date
ES8400770A1 true ES8400770A1 (es) 1983-11-01
ES509222A0 ES509222A0 (es) 1983-11-01

Family

ID=27224760

Family Applications (2)

Application Number Title Priority Date Filing Date
ES498343A Expired ES8308534A1 (es) 1980-01-08 1981-01-07 Un metodo de producir un polipeptido que exhibe actividad inmunologica o biologica del interferon de leucocitos humanos.
ES509222A Granted ES509222A0 (es) 1980-01-08 1982-02-01 Un metodo para producir una molecula de adn recombinante caracterizada por una secuencia de adn codificada de un coni- peptido semejante al, interferon humano.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES498343A Expired ES8308534A1 (es) 1980-01-08 1981-01-07 Un metodo de producir un polipeptido que exhibe actividad inmunologica o biologica del interferon de leucocitos humanos.

Country Status (22)

Country Link
EP (1) EP0032134B2 (es)
JP (1) JP2501889B2 (es)
AU (1) AU553400B2 (es)
CA (1) CA1341567C (es)
CY (1) CY1346A (es)
DD (2) DD159782A5 (es)
DE (1) DE3165463D1 (es)
DK (2) DK170236B1 (es)
ES (2) ES8308534A1 (es)
FI (1) FI86558C (es)
GR (1) GR73557B (es)
HU (1) HU194305B (es)
IE (1) IE54096B1 (es)
MY (1) MY8700559A (es)
NO (2) NO164037C (es)
NZ (1) NZ195980A (es)
OA (1) OA06717A (es)
PH (1) PH21848A (es)
PL (1) PL148434B1 (es)
PT (1) PT72322B (es)
SG (1) SG77286G (es)
YU (1) YU45533B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI77877C (fi) * 1979-04-20 1989-05-10 Technobiotic Ltd Foerfarande foer framstaellning och rening av human le-formig interferonprotein.
DE3005897A1 (de) * 1980-02-16 1981-09-03 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus
DE3005843A1 (de) * 1980-02-16 1981-09-10 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enthaltenden mikroorganismus
DE3177213D1 (de) 1980-04-03 1990-10-18 Biogen Inc Dns-sequenzen, rekombinante dns-molekuele und verfahren zur herstellung von dem menschlichen fibroblast-interferon.
EP0042246B1 (en) * 1980-06-12 1987-03-18 The Cancer Institute Of Japanese Foundation For Cancer Research Plasmid
CH651308A5 (de) * 1980-07-01 1985-09-13 Hoffmann La Roche Interferone und deren herstellung.
ES506955A0 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
DE3280127D1 (de) * 1981-03-27 1990-04-12 Ici Plc Genetisch modifizierte mikroorganismen.
EP0085693A1 (en) * 1981-08-14 1983-08-17 A/S Alfred Benzon Subjects relating to human inteferon-alpha subtype proteins and corresponding antibodies
GB2108510B (en) * 1981-10-03 1984-12-12 Ciba Geigy Ag Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof
US4973479A (en) * 1982-01-15 1990-11-27 Cetus Corporation Interferon-α61
US5098703A (en) * 1982-01-15 1992-03-24 Cetus Corporation Interferon-alpha 76
US4975276A (en) * 1982-01-15 1990-12-04 Cetus Corporation Interferon-alpha 54
IE54592B1 (en) * 1982-03-08 1989-12-06 Genentech Inc Anumal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and espression vehicles containing such sequences and cells transformed thereby
US5827694A (en) * 1982-03-08 1998-10-27 Genentech, Inc. DNA encoding non-human animal interferons, vectors and hosts therefor, and recombinant production of IFN polypeptides
DE3220116A1 (de) * 1982-05-28 1983-12-01 Dr. Karl Thomae Gmbh, 7950 Biberach Mikrobiologisch hergestellte (alpha)- und ss-interferone, dna-sequenzen, die fuer diese interferone codieren, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung
US5831023A (en) * 1982-11-01 1998-11-03 Genentech, Inc. Recombinant animal interferon polypeptides
GB8315980D0 (en) * 1983-06-10 1983-07-13 Biogen Nv Producing hybrid dna sequences
US4892743A (en) * 1983-12-21 1990-01-09 Schering Corporation Novel hybrid interferon species
EP0146903A3 (en) * 1983-12-19 1987-07-22 Schering Corporation Production of a vector encoding a novel hybrid interferon species
FR2560212B1 (fr) * 1984-02-24 1989-12-29 Unicet Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
US5231176A (en) * 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
EP0174143B1 (en) * 1984-08-27 1989-11-08 Genentech, Inc. Novel, distinct family of human leukocyte interferons, compositions containing them, methods for their production, and dna and transfected hosts therefor
IL76360A0 (en) * 1984-09-26 1986-01-31 Takeda Chemical Industries Ltd Mutual separation of proteins
EP0194006B1 (en) * 1985-02-01 1992-04-29 Imperial Chemical Industries Plc Analogous interferon polypeptides, process for their preparation and pharmaceutical compositions containing them
SE8502430L (sv) * 1985-05-15 1986-11-16 Kabivitrum Ab En cdna-molekyl som kodar for expressionen av en polypeptid av typen interferon alfa, en bakteriell eller celluler verd transformerad med en sadan molekyl och en polypeptid som uppvisar interferonaktivetet framstelld me
DE3685996T2 (de) * 1985-06-11 1993-01-14 Ciba Geigy Ag Hybrid-interferone.
ATE93541T1 (de) * 1985-07-03 1993-09-15 Genencor Int Hybride polypeptide und verfahren zu deren herstellung.
US4846782A (en) * 1986-03-14 1989-07-11 Schering Corporation Treatment of cancer with interferon and radiotherapy
ES2074420T3 (es) 1986-04-15 1995-09-16 Ciba Geigy Ag Anticuerpos monoclonales contra proteina humana inducida por interferon en forma pura y kits de ensayo que contienen dichos anticuerpos.
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US4851220A (en) * 1986-11-26 1989-07-25 Schering Corporation Stable oleaginous gel
US5190751A (en) * 1987-01-20 1993-03-02 Schering Corporation Treatment of certain leukemias with a combination of gamma interferon and alpha interferon
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
US4871538A (en) * 1987-07-13 1989-10-03 Schering Corporation Insoluble copper-alpha interferon complex
GB8813032D0 (en) * 1988-06-02 1988-07-06 Boehringer Ingelheim Int Antiviral pharmaceutical composition
US5256410A (en) * 1988-12-01 1993-10-26 Schering Corporation Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
WO1999029863A1 (en) 1997-12-08 1999-06-17 Genentech, Inc. Human interferon-epsilon: a type i interferon
ZA9811070B (en) 1997-12-08 2000-07-03 Genentech Inc Type I interferons.
SK287372B6 (sk) 1998-11-12 2010-08-09 Schering Corporation Spôsob zvýšenia výťažku prostriedku obsahujúceho interferón-alfa
US6281337B1 (en) 1998-11-12 2001-08-28 Schering Corporation Methods for conversion of protein isoforms
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
AU2001255380A1 (en) * 2000-04-14 2001-10-30 Zymogenetics Inc. Human interferon, zinf2
ATE360696T1 (de) * 2000-06-30 2007-05-15 Zymogenetics Inc Interferon-ähnliches protein zcyto21
US7959910B2 (en) 2000-07-31 2011-06-14 Biolex Therapeutics, Inc. C-terminally truncated interferon alpha variants
FR2823220B1 (fr) 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
US7038032B2 (en) 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
US7910313B2 (en) 2001-04-20 2011-03-22 Zymogenetics, Inc. Cytokine protein family
BR0205083A (pt) * 2001-04-20 2004-07-20 Zymogenetics Inc Polipeptìdeo isolado, composição farmacêutica, proteìna de fusão, polinucleotìdeo isolado, vetor de expressão, célula hospedeira recombinante e métodos de produzir um polipeptìdeo, de detectar a presença da expressão de gene em uma amostra biológica, de expandir células monocìticas ou progenitores de células de monócitos e de estimular uma resposta imune em um mamìfero exposto a um antìgeno ou patógeno
FR2824333B1 (fr) 2001-05-03 2003-08-08 Genodyssee Nouveaux polynucleotides et polypeptides de l'ifn alpha 5
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
JP2006509041A (ja) 2002-10-23 2006-03-16 ザイモジェネティクス，インコーポレイティド Ｉｌ−２８およびｉｌ−２９を用いるウイルス感染を治療するための方法
AU2002356422A1 (en) * 2002-11-01 2004-05-25 Cadila Healthcare Limited Mthod for producing recombinant human interferon alpha 2b polypeptide in pichia pastoris
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
PT2251353E (pt) 2003-08-07 2013-05-07 Zymogenetics Inc Preparações homogéneas de il-28 e il-29
JP4896005B2 (ja) 2004-04-02 2012-03-14 ザイモジェネティクス リミテッド ライアビリティ カンパニー Ｉｌ−２８およびｉｌ−２９システイン変異体を用いるウイルス感染を治療するための方法
WO2006012644A2 (en) 2004-07-29 2006-02-02 Zymogenetics, Inc. Use of il-28 and il-29 to treat cancer
US20060024272A1 (en) 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
WO2006095433A1 (ja) * 2005-03-10 2006-09-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo ウシの消化器疾患治療剤
AU2006272937A1 (en) 2005-07-20 2007-02-01 Bristol-Myers Squibb Company Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders
US8273561B2 (en) 2007-10-05 2012-09-25 Nuron Biotech, Inc. High pressure treatment of aggregated interferons
CA2746502A1 (en) 2008-12-23 2010-07-01 Xiaoyu Yang Purification of recombinantly produced interferon
WO2019226050A2 (en) * 2018-05-24 2019-11-28 Wageningen Universiteit Novel viral anti-infective reagents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MW3378A1 (en) * 1977-11-08 1980-03-12 Genentech Inc Method and means for microbial polypeptide expression;synthetic dna and process therefor
AU538665B2 (en) * 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna

Also Published As

Publication number Publication date
NO810041L (no) 1981-07-09
FI86558C (fi) 1992-09-10
JP2501889B2 (ja) 1996-05-29
FI810030L (fi) 1981-07-09
OA06717A (fr) 1982-06-30
NO850733L (no) 1981-07-09
GR73557B (es) 1984-03-15
PH21848A (en) 1988-03-17
AU6605781A (en) 1981-07-30
DK61595A (da) 1995-05-31
IE810025L (en) 1981-07-08
DD159782A5 (de) 1983-04-06
NO164037C (no) 1990-08-22
EP0032134B2 (en) 1993-10-13
YU45533B (en) 1992-05-28
EP0032134B1 (en) 1984-08-15
PL148434B1 (en) 1989-10-31
EP0032134A2 (en) 1981-07-15
MY8700559A (en) 1987-12-31
ES509222A0 (es) 1983-11-01
SG77286G (en) 1987-02-27
DK5681A (da) 1981-07-09
PT72322B (en) 1982-09-23
YU2681A (en) 1983-12-31
HU194305B (en) 1988-01-28
AU553400B2 (en) 1986-07-17
EP0032134A3 (en) 1981-08-26
DK170236B1 (da) 1995-07-10
DD203071A5 (de) 1983-10-12
PL229123A1 (en) 1983-07-18
PT72322A (en) 1981-03-01
DE3165463D1 (en) 1984-09-20
CY1346A (en) 1987-01-16
ES498343A0 (es) 1983-09-01
NZ195980A (en) 1984-10-19
JPH02131431A (ja) 1990-05-21
FI86558B (fi) 1992-05-29
IE54096B1 (en) 1989-06-21
ES8308534A1 (es) 1983-09-01
CA1341567C (en) 2008-02-19
NO164037B (no) 1990-05-14

Similar Documents

Publication Publication Date Title
ES8308534A1 (es) Un metodo de producir un polipeptido que exhibe actividad inmunologica o biologica del interferon de leucocitos humanos.
ES8403969A1 (es) Un metodo para producir polipetido semejante a interferon inmune humano.
ES8506347A1 (es) Un metodo para producir un polipeptido de tipo il-2-".
ZA81103B (en) Dna sequences ,recombinant dna molecules dna molecules and processes for producing human interferon -like polypeptides
ES8504936A1 (es) Procedimiento para preparar polipeptidos.
IL64243A (en) Hybrid human leukocyte interferon type anti-viral polypeptides,their preparation by genetic engineering methods and pharmaceutical compositions containing them
IL70414A (en) Polypeptide having human h2-relaxin activity,double-stranded dna fragments coding therefor,vectors containing the dna fragments and methods for preparing the polypeptide,dna fragments and vectors
ES8303529A1 (es) Un procedimiento para la produccion de un plasmido recombi- nante.
JPS55104887A (en) Rearranged dna molecule and method
ZA86217B (en) Dna sequences,recombinant dna molecules and processes for producing human lipocortin-like polypeptides
IE832259L (en) Dna sequences swine growth hormone polypeptides
NZ212937A (en) Omega interferons: production by recombinant dna processes; pharmaceutical compositions
EP0091527A3 (en) Dna sequences, recombinant dna molecules and processes for producing human serum albumin-like polypeptides
DE69013811D1 (de) Verfahren zur Herstellung von antiviralem Protein unter Benützung von E.coli-Transformant, das Gen, das für dieses Protein kodiert und E.coli-Vektor benützt in diesem Verfahren.
GEP19970665B (en) Processes for producing human interferon-like polypeptides
EP0215110A4 (en) MANUFACTURING SOMATOMEDIN C.
ZA84512B (en) Dna sequences,recombinant dna molecules and processes for producing human interleukin two-like polypeptides
KE3669A (en) Dna sequences,recombinant dna molecules and processes for producing human interferon-alpha like polypeptides
HRP921091B1 (en) Dna sequences, recombinant dna molecules and processes for producing human fibroplast interferon-like polypeptides
ZA812189B (en) Dna sequences, recombinant dna molecules and processes for producing human fibroblast interferon-like polypeptides
ES8700694A1 (es) Un procedimiento para producir un polipeptido de interferon hibrido antivirico y antiproliferante
IL61872A (en) Dna sequences,recombinant dna molecules,processes for producing human interferon alpha-type polypeptides and pharmaceutical and veterinary compositions containing them
SG134394G (en) Genetic sequences, type I interferon peptide coded by them, and these organisms producing the same
Hooks Molecular aspects and biological functions of interferon
IL77830A (en) Dna sequences, recombinant dna molecules and processes for producing human b-interferon

Legal Events

Date Code Title Description
PC1A Transfer granted

Owner name: BIOGEN, INC.